读了《中级医刊》1985年第6期刊登的“维生素K_3在治疗毛细支气管炎中的止喘作用(附86例总结)”一文,很受启发。但感到其中也存在一些问题,提几点意见供参考。 1.维生素K_3注射剂目前生产的均是供肌肉注射的制剂,将肌肉注射制剂用于静脉点滴是否安全?尽管作者的病例未发生任何副作用,但此问题仍令人疑虑。另外,“将总量K_3加入10％葡萄糖液50毫升中静脉点滴”,K_3在血中高峰浓度出现的时间是否较肌肉注射出现的早也值得探讨。各种维生素K肌肉注射均很快被吸收,而加入50毫升液体中静脉点滴按肺炎常规输液速度每小时每公斤体重5毫升计算,小于1岁者均需1小时以上方能滴完。这样静脉点滴用药血中K_3高峰浓度出现的时间不一定比肌肉注射早。基于上述原因,我认为K_3以肌肉注射为宜。有些文献报告K_1也有明显止喘作用,因此如确需静脉给药,以选 Read the “Intermediate Medical Journal” No. 6, 1985, published in “vitamin K_3 in the treatment of bronchitis in the role of asthma (with 86 cases summary)” article, very inspired. However, there are also some problems that I feel are some suggestions for reference. 1. Vitamin K_3 injections are currently produced for intramuscular injections. Is it safe to use intramuscular injections for intravenous injections? Although no adverse effects have been reported in the authors’ cases, this issue remains a cause for concern. In addition, “the total amount of K_3 added 10% glucose solution 50 ml intravenous drip”, K_3 in the blood peak concentration occurs earlier than the intramuscular injection is also worth exploring. A variety of vitamin K intramuscular injection are quickly absorbed, and add 50 ml of liquid in the intravenous infusion of pneumonia by conventional infusion rate of 5 ml per kg body weight per hour, less than 1 year old people need more than 1 hour before dropping. Such intravenous drip medication K_3 peak concentration appears not necessarily earlier than intramuscular injection. For the above reasons, I think K_3 intramuscular injection is appropriate. Some literature reports K_1 also has a significant anti-asthma effect, so if the need for intravenous administration, to elect